Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Trotabresib + Vinorelbine + RT in HER2+ Breast Cancer CNS Metastasis
NCT06137651Phase 1Withdrawn
- Sponsor
- Northwestern University
- Start
- Dec 2023
- Primary completion
- Mar 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of trotabresib in HER2-positive breast cancer (2 cohorts), sponsored by Northwestern University. Primary endpoints: Maximum Tolerated Dose at 28 days and Incidence of Adverse Events at 30 days. Planned start Dec 2023; status: withdrawn.
02
Drugs
trotabresib
03
Conditions
HER2-positive breast cancer
Beyond the preview
Go deeper on NCT06137651.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06137651.